Protagonist Therapeutics received sizable payments from Johnson & Johnson for product milestones.
3 reports, 2 independent
Updated Aug 31
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Protagonist Therapeutics received sizable payments from Johnson & Johnson for product milestones.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Protagonist Therapeutics (United States)
company in Milpitas, United States
Nothing else this week.
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Related events
- Johnson & Johnson highlighted growth opportunities within the MedTech sector.
- Johnson & Johnson is reportedly considering a sale of its orthopedics business unit within DePuy Synthes.
- Johnson & Johnson, UnitedHealth Group, and Intuitive Surgical are noted as major players in the high-volume U.S. healthcare sector.
- MedTech is identified as a soft spot in J&J case.
Coverage
Newest first; wire copies grouped- fool.com
- Simply Wall St.Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot? Protagonist Therapeutics recently announced its second quarter 2025 earnings, reporting a net loss